

Patricio Escalante

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4762818/publications.pdf>

Version: 2024-02-01

35
papers

422
citations

759233

12
h-index

752698

20
g-index

36
all docs

36
docs citations

36
times ranked

738
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 265-275.	10.7	80
2	Cough Due to TB and Other Chronic Infections. <i>Chest</i> , 2018, 153, 467-497.	0.8	36
3	Pharmacotherapy Approaches in Nontuberculous Mycobacteria Infections. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1567-1581.	3.0	33
4	Antifungal prophylaxis in lung transplant: A survey of United States' transplant centers. <i>Clinical Transplantation</i> , 2019, 33, e13630.	1.6	31
5	Combinatorial Immunoprofiling in Latent Tuberculosis Infection. Toward Better Risk Stratification. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 605-617.	5.6	28
6	T-Cell Profiling and the Immunodiagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 329-338.	1.9	22
7	High rates of tuberculin skin test positivity due to methotrexate therapy: False positive results?. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 538-546.	3.4	20
8	Risk assessment of latent tuberculosis infection through a multiplexed cytokine biosensor assay and machine learning feature selection. <i>Scientific Reports</i> , 2021, 11, 20544.	3.3	20
9	Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 834981.	4.8	19
10	Tuberculosis patient and family education through videography in El Salvador. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2016, 4, 14-20.	1.3	14
11	Characteristics of Mycobacterium avium complex (MAC) pulmonary disease in previously treated lung cancer patients. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 70-73.	0.4	13
12	Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2272-2277.	1.9	13
13	Precision immunoprofiling to reveal diagnostic signatures for latent tuberculosis infection and reactivation risk stratification. <i>Integrative Biology (United Kingdom)</i> , 2019, 11, 16-25.	1.3	13
14	Microencapsulated Immunoassays for Detection of Cytokines in Human Blood. <i>ACS Sensors</i> , 2019, 4, 578-585.	7.8	12
15	Management and diagnosis of tuberculosis in solid organ transplant candidates and recipients: Expert survey and updated review. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2018, 11, 37-46.	1.3	10
16	Positive Pneumocystis jirovecii Sputum PCR Results with Negative Bronchoscopic PCR Results in Suspected Pneumocystis Pneumonia. <i>Canadian Respiratory Journal</i> , 2018, 2018, 1-5.	1.6	8
17	Diagnosis of Latent Tuberculosis Infection with T-SPOT®.TB in a Predominantly Immigrant Population with Rheumatologic Disorders. <i>Lung</i> , 2015, 193, 3-11.	3.3	7
18	The Role of Biofilms, Bacterial Phenotypes, and Innate Immune Response in Mycobacterium avium Colonization to Infection. <i>Journal of Theoretical Biology</i> , 2022, 534, 110949.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Non-antimicrobial airway management of non-cystic fibrosis bronchiectasis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2018, 10, 24-28.	1.3	6
20	Clinical and Epidemiological Correlates of Low IFN-Gamma Responses in Mitogen Tube of QuantiFERON Assay in Tuberculosis Infection Screening During the COVID-19 Pandemic: A Population-Based Marker of COVID-19 Mortality?. <i>Archivos De Bronconeumologia</i> , 2022, 58, 649-659.	0.8	6
21	Anti-synthetase syndrome presenting as cryptogenic organizing pneumonia. <i>Respiratory Medicine Case Reports</i> , 2012, 6, 13-15.	0.4	4
22	Flow Cytometric Immune Profiling in Infliximab-Associated Tuberculosis. <i>Clinical Medicine Insights: Case Reports</i> , 2017, 10, 117954761772477.	0.7	4
23	Active and latent tuberculosis infections in patients treated with immune checkpoint inhibitors in a non-endemic tuberculosis area. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3105-3111.	4.2	4
24	<i>Citrobacter koseri</i> Pneumonia as Initial Presentation of Underlying Pulmonary Adenocarcinoma. <i>Clinical Medicine Insights: Case Reports</i> , 2016, 9, CCRRep.S40616.	0.7	3
25	Progress Towards Developing a Rapid Triage/Referral Test for Tuberculosis. <i>Clinical Chemistry</i> , 2020, 66, 995-997.	3.2	2
26	Nuevos enfoques en investigación de la infección tuberculosa latente. <i>Archivos De Bronconeumologia</i> , 2021, 57, 151-153.	0.8	2
27	Novel Treatments for Drug-Resistant Tuberculosis. <i>Clinical Medicine Insights Therapeutics</i> , 2016, 8, CMT.S18560.	0.4	1
28	51-Year-Old Man With Fever and Productive Cough. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2308-2313.	3.0	1
29	New Diagnostics to Infer Risk in Tuberculosis: Is the Term "Latent Tuberculosis Infection" Obsolete?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1460-1461.	5.6	1
30	65-Year-Old Man With Weight Loss and Dyspnea on Exertion. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1363-1368.	3.0	1
31	Nuevas perspectivas en infección tuberculosa latente. <i>Archivos De Bronconeumologia</i> , 2020, 56, 74-75.	0.8	0
32	Cavitary lung lesions caused by <i>Pneumocystis jirovecii</i> in setting of common variable immune deficiency. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101277.	0.4	0
33	Cascade of Care in the Management of Latent Tuberculosis Infection in the United States: A Lot to Improve and to Scale Up. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1620-1621.	3.2	0
34	A 70-Year-Old Man With Cough and Recurrent Respiratory Infections. <i>Chest</i> , 2021, 160, e347-e350.	0.8	0
35	Characteristics and outcomes of anti-mycobacterial therapy compared to no anti-mycobacterial therapy for NTM pulmonary disease. <i>Respiratory Medicine</i> , 2022, 197, 106829.	2.9	0